DeCure's autonomous Cancer AI scientist is researching a drug-repurposing hypothesis for uterine corpus adenosarcoma — screening already-approved drugs against its 44-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleUterine corpus adenosarcoma maps to a 44-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for uterine corpus adenosarcoma is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
NRAS proto-oncogene, GTPase (NRAS) — NRAS is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet gdpdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 6ZIO · 1.55 Å · ligand GUANOSINE-5'-DIPHOSPHATE (GDP). Experimental structure, not a prediction.
What the evidence adds up to
A 2022 case report describes a 46-year-old woman with uterine adenosarcoma originating in the lower uterine segment, diagnosed by endometrial biopsy and confirmed in the complete surgical specimen, with both identifying heterologous malignant elements. A 2024 case report notes that adenosarcoma mainly affects the endometrium (71%) and less frequently the cervix (2%), and that it should be considered in post-menopausal bleeding.
A 2019 retrospective single-centre study reviewed 49 cases of uterine adenosarcoma between 2006 and 2018. Median follow-up was 34 months (range 1–148). Median age was 47.5 years (range 19–75). Nineteen patients (38.9%) had cervical adenosarcoma and 30 (61.22%) had uterine corpus adenosarcoma. Twenty-nine patients (59.2%) had polypoid tumours with a stalk. Twenty-six patients (38.8%) were stage IA. Fifteen patients (30.6%) showed sarcomatous overgrowth. Six patients (12.2%) had lymphovascular space invasion (LVSI). Four patients (8.16%) had heterologous elements. In univariate analysis, disease-free survival was associated with tumour location, presence of a tumour stalk, heterologous elements, and LVSI. In multivariate analysis, presence of a tumour stalk was an independent protective factor for recurrence (HR = 0.088, P = 0.005), and LVSI was a risk factor for recurrence (HR = 11.953, P = 0.002). Fertility-sparing surgery was performed in seven stage IA patients; when stage IA patients were analysed separately, fertility-sparing surgery was not significantly associated with disease-free or overall survival.
No drug treatment is mentioned in any of these abstracts. The evidence consists entirely of case reports and a single-centre retrospective series. What is missing are prospective trials, any data on systemic therapy, and patient stratification beyond the small set of histologic and surgical variables examined here.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Frontiers in Medicine · 2022 · 8 citations · open access
Case Report: Uterine Adenosarcoma With Sarcomatous Overgrowth and Malignant Heterologous Elements
AbstractA 46- year-old woman presented a uterine adenosarcoma originating in the lower uterine segment. The diagnosis was made in an endometrial biopsy and confirmed in the pathological examination of the complete surgical specimen, both identifying heterologous malignant elements. In addition, complementary immunohistochemical studies were performed. We reviewed the literature, illustrating the clinical and morphological characteristics and the differential diagnoses to be evaluated.
Clinical Case Reports · 2024 · 2 citations · open access
Unveiling the intriguing <scp>grape‐like</scp> mass: Uterine cervical adenosarcoma
AbstractKey Clinical Message: Adenosarcoma of the uterine cervix should be considered in the evaluation of post-menopausal bleeding, as it can be a potential underlying cause. Timely diagnosis and appropriate management are essential to optimize patient outcomes. Abstract: Adenosarcoma is a biphasic neoplasm comprising both a benign epithelial component and a typically low-grade sarcomatous stromal component. Adenosarcoma mainly affects the endometrium (71%), with a lesser incidence in the cervix (2%). Herein, the authors report a case of adenosarcoma of the uterine cervix with distinct gross features.
Image_1_Uterine Adenosarcoma: A Retrospective 12-Year Single-Center Study.TIF
Abstract<p>Synopsis: Lymphovascular space invasion is an independent risk factor for disease progression and presence of tumor stalk an independent protective factor. Fertility sparing surgery may be acceptable in cases whose tumors present with stalks and without high risk factors.</p><p>Objectives: The aim of the present study was to investigate the potential prognostic factors of uterine adenosarcoma.</p><p>Methods: A total of 49 cases of uterine adenosarcoma were retrospectively reviewed at our institution between April 2006 and October 2018.</p><p>Results: Median follow-up time was 34 months (range: 1–148). Median age was 47.50 years (19–75). Nineteen (38.9%) patients were uterine cervical adenosarcoma and 30 (61.22%) patients were uterine corpus adenosarcoma. Twenty-nine (59.2%) patients were polypoid with a stalk to the uterine cervix or corpus. Twenty-six (38.8%) patients were stage IA. Fifteen (30.6%) patients showed sarcomatous overgrowth. Six (12.2%) patients displayed lymphovascular space invasion (LVSI). Four (8.16%) patients had heterologous elements. In univariate analysis, Disease-free-survival (DFS) was associated with tumor location, presence of tumor stalk, heterologous elements, LVSI. In multivariate analysis, presence of tumor stalk remained an independently protective factor for recurrence (HR = 0.088, P = 0.005), and LVSI a risk factor for recurrence (HR = 11.953, P = 0.002). Fertility-sparing surgery (FSS) was performed in seven stage IA patients. When patients of stage IA analyzed separately, FSS was not significant with the DFS or OS.</p><p>Conclusions: Presence of tumor stalk remained an independently protective factor for recurrence. Along with adequate counseling, FSS may be acceptable in cases whose tumors present with stalks and without high risk factors.</p>
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
